Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

The approval of Opdivo Qvantig was supported by data from the randomized, open-label phase 3 CheckMate-67T study.

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...

The FDA approved an injectable version of Opdivo, a cancer drug by Bristol Myers Squibb. Axsome plans to seek approval for ...

Opdivo Qvantig (nivolumab and hyaluronidase) has been approved for use across almost all of Opdivo's lengthy list of ...

Halozyme's attempt to acquire Evotec was a bold move to diversify revenue, but was ultimately unsuccessful, impacting HALO's ...

The FDA approves an injectable Opdivo cancer drug; Axsome seeks approval for an Alzheimer's drug amid mixed results; Hain ...

Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...

The FDA has approved subcutaneous nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) to treat a range of solid tumor malignancies.

BMSs Opdivo gains FDA approval for faster subcutaneous cancer treatment BMS secures FDA nod for rapid cancer treatment ...